DuRoss Amy 4
4 · BIOLIFE SOLUTIONS INC · Filed Mar 13, 2024
Insider Transaction Report
Form 4
DuRoss Amy
Director
Transactions
- Award
Common Stock
2024-03-08+11,264→ 40,643 total - Sale
Common Stock
2024-03-12$16.86/sh−6,135$103,436→ 34,508 total - Sale
Common Stock
2024-03-13$17.00/sh−5,065$86,105→ 29,443 total
Footnotes (2)
- [F1]The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.60 to $17.11, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.